Recently, a CRISPR/Cas9-based mutant enrichment technique revealed a 93.9% sensitivity and 100% specificity in detecting EGFR T790M mutation in cfDNA from patients with NSCLC [79]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.